Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPO | P05164 | 1/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
| ▸ | KIF11 | P52732 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.36 |
| ▸ | KDR | P35968 | 3/20 | 0.36 |
| ▸ | KIT | P10721 | 2/20 | 0.36 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.36 |
| ▸ | LYN | P07948 | 1/20 | 0.36 |
| ▸ | BRAF | P15056 | 1/20 | 0.36 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31344595 | 1.00 | MPO (0.39) | MPORXFP1KIF11POLBKDM4E | |
| SCHEMBL6772842 | 0.89 | KCNK3 (0.46) | MPORXFP1POLBKDM4EDDR2 | |
| SCHEMBL31344596 | 0.85 | RORC (0.35) | KDRKITGAAAHRHSD17B10 | |
| SCHEMBL6776081 | 0.85 | RORC (0.35) | KDRKITGAAAHRHSD17B10 | |
| SCHEMBL31337247 | 0.84 | CHEK2 (0.36) | — | |
| SCHEMBL31337191 | 0.84 | GPR35 (0.41) | MPORXFP1KDM4EALDH1A1HTT | |
| SCHEMBL6772436 | 0.84 | GPR35 (0.41) | MPORXFP1KDM4EALDH1A1HTT | |
| SCHEMBL31337135 | 0.84 | GPR35 (0.34) | HTTSMN1; SMN2KDRGAAAHR | |
| SCHEMBL6782022 | 0.84 | GPR35 (0.34) | HTTSMN1; SMN2KDRGAAAHR | |
| SCHEMBL6775914 | 0.83 | KIF11 (0.37) | KIF11KDRKITLYNFYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0977741-B1 | SUBSTITUTED PHENYL DERIVATIVES, THEIR PREPARATION AND USE | NEUROSEARCH AS (DK) | 2003-09-03 | — | — | EP | claimed |
| US-6297261-B1 | POTENT CHLORIDE CHANNEL BLOCKERS; TREATMENT OF SICKLE CELL ANEMIA, BRAIN EDEMA FOLLOWING ISCHAEMIA OR TUMORS, DIARRHEA, HYPERTENSION (DIURETIC), OSTEOPOROSIS, AND FOR THE REDUCTION OF THE INTRAOCULAR PRESSURE | NEUROSEARCH A/S (DK) | 2001-10-02 | — | — | US | claimed |
| EP-0977741-A1 | SUBSTITUTED PHENYL DERIVATIVES, THEIR PREPARATION AND USE | NEUROSEARCH A/S (DK) | 2000-02-09 | — | — | EP | claimed |
| WO-1998047879-A1 | SUBSTITUTED PHENYL DERIVATIVES, THEIR PREPARATION AND USE | NEUROSEARCH A/S (DK) | 1998-10-29 | — | — | WO | claimed |
| US-6696475-B2 | N-PHENYL-N'-(2-CARBOXYPHENYL) UREA, FOR EXAMPLE; CHLORIDE CHANNEL BLOCKERS; SUCH AS FOR TREATING BONE METABOLIC DISORDERS | NEUROSEARCH A/S (DK) | 2004-02-24 | — | — | US | disclosed |
| EP-0977741-B1 | SUBSTITUTED PHENYL DERIVATIVES, THEIR PREPARATION AND USE | NEUROSEARCH AS (DK) | 2003-09-03 | — | — | EP | disclosed |
| US-20020037905-A1 | Substituted phenyl derivatives, their preparation and use | ANIONA APS (DK) | 2002-03-28 | — | — | US | disclosed |
| US-6297261-B1 | POTENT CHLORIDE CHANNEL BLOCKERS; TREATMENT OF SICKLE CELL ANEMIA, BRAIN EDEMA FOLLOWING ISCHAEMIA OR TUMORS, DIARRHEA, HYPERTENSION (DIURETIC), OSTEOPOROSIS, AND FOR THE REDUCTION OF THE INTRAOCULAR PRESSURE | NEUROSEARCH A/S (DK) | 2001-10-02 | — | — | US | disclosed |
| EP-0977741-A1 | SUBSTITUTED PHENYL DERIVATIVES, THEIR PREPARATION AND USE | NEUROSEARCH A/S (DK) | 2000-02-09 | — | — | EP | disclosed |
| WO-1998047879-A1 | SUBSTITUTED PHENYL DERIVATIVES, THEIR PREPARATION AND USE | NEUROSEARCH A/S (DK) | 1998-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020037905-A1 | Substituted phenyl derivatives, their preparation and use | KCNB1, KCNH2, KCNJ2 | MPO 2457/4885RXFP1 2193/4885KIF11 2445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.